Compound Library

Educational summaries organized by evidence maturity, limitations, and regulatory context.

Evidence across the library

How tracked compounds distribute by human-evidence grade. Most sit in C–D — an honest picture of the peptide literature.

Browsing is free. Full evidence-graded research reports, graphs, and comparison tools are part of Vial+ ($20 one-time).

Showing 8 free-tier results

Semaglutide

A

Metabolic · Body Composition

A selective GLP-1 receptor agonist FDA-approved across type 2 diabetes, chronic weight management, and cardiovascular risk reduction in adults with overweight or obesity and cardiovascular disease.

Tirzepatide

A

Metabolic · Body Composition

A dual GIP and GLP-1 receptor agonist with FDA approvals across type 2 diabetes, chronic weight management, and obstructive sleep apnea in obesity.

Retatrutide

B

Body Composition · Metabolic

An investigational triple agonist of GIP, GLP-1, and glucagon receptors in late-stage clinical trials for obesity and related conditions.

BPC-157

D

Healing · Gut

A 15-amino-acid synthetic peptide fragment derived from a gastric juice protein, widely promoted for soft-tissue healing despite an evidence base dominated by rodent studies.

TB-500 (Thymosin Beta-4)

C

Healing · Cardiovascular

A naturally occurring 43-amino-acid actin-sequestering peptide investigated for wound healing, dry eye, and cardiac repair, with mixed Phase 2 readouts and no FDA approval.

Cagrilintide

B

Metabolic · Body Composition

A long-acting amylin analog under Phase 3 investigation primarily in combination with semaglutide (CagriSema) for obesity and type 2 diabetes.

MK-677 (Ibutamoren)

B

Growth Hormone · Body Composition

An orally active non-peptide ghrelin receptor agonist studied in Phase 2 trials for frailty, hip fracture recovery, and growth hormone deficiency.

Ipamorelin

C

Growth Hormone · Endocrine

A selective ghrelin-receptor agonist pentapeptide developed by Novo Nordisk that triggered GH release without elevating cortisol or prolactin, with clinical development discontinued after Phase 2 trials in postoperative ileus.